OBI Pharma, Inc

OBI Pharma Inc. (OBI) is a global clinical stage oncology company that is headquartered in Taiwan. The company also has subsidiaries in the United States and Australia. It was founded in 2002 by Dr. Michael Chang, an accomplished biotech entrepreneur in the United States. Its stocks were issued publicly in 2012. Subsequently, the company was successfully listed on the Taipei Exchange (TWO. 4174) in 2015. OBI focuses on innovative research and development for cancer therapies and aims to develop “first-in-class” and “best-in-class” ground-breaking drugs. It aspires to market these drugs worldwide with a “Made in Taiwan” branding and to provide new treatment options for patients with unmet medical needs. The core value of OBI lies in its passion to develop and deliver a portfolio of unique antibody-drug conjugates (ADC) drugs for patients, in addition to its promising Globo series (e.g., Globo H) of cancer therapeutic vaccines. This evolving portfolio includes a spectrum of cancer targets, such as TROP2, Nectin4, HER2, etc. These ADCs are built based on two distinct ADC technology platforms, each with different characteristics. Both platforms are customizable and offer a “plug-and-play” advantage through a specialized site-specific conjugation using a proprietary enzyme. With the added value of scalability, these “plug-and-play” technology platforms enable ADC development to be relatively simple and efficient. OBI is interested in commercializing its ADC technology platforms and looks forward to collaborating with biotech and pharmaceutical companies by enabling “first-in-class” and “best-in-class” therapeutic candidates for further development.